Global Targeted Therapy Drugs for Cancer market size is predicted to grow from US$ 118360 million in 2025 to US$ 191441 million in 2032; it is expected to grow at a CAGR of 7.6% from 2026 to 2032.

Global Targeted Therapy Drugs for Cancer Market Trends, Growth | CAGR Of 7.6%

The global Targeted Therapy Drugs for Cancer market size is predicted to grow from US$ 118360 million in 2025 to US$ 191441 million in 2032; it is expected to grow at a CAGR of 7.6% from 2026 to 2032. In 2025, global Targeted Therapy Drugs for Cancer reached approximately 58.76 M Units, with an average global market price of around 2059 USD per Unit. Targeted therapy drugs for cancer are anticancer medicines designed to specifically interfere with molecular targets?such as mutated genes, abnormal proteins, or dysregulated signaling pathways?that drive the growth, survival, or spread of cancer cells. These targets are typically involved in processes like cell proliferation, angiogenesis, DNA repair, or immune evasion, and are more active or uniquely altered in cancer cells compared with normal cells. Unlike traditional chemotherapy, which broadly affects rapidly dividing cells, targeted cancer therapies act in a more precise and mechanism-driven manner, aiming to block cancer-specific biological processes while minimizing damage to healthy tissues. They include small-molecule drugs (often taken orally and acting inside cells) and biologic agents such as monoclonal antibodies (usually acting on cell-surface targets or extracellular ligands). Targeted therapies are commonly selected based on biomarker or genetic testing, making them a central component of precision oncology. The upstream raw materials for Targeted Therapy Drugs for Cancer mainly include active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and excipients. Typical suppliers include Pfizer, Roche, Merck, and AstraZeneca. Downstream applications are primarily in oncology and rare disease treatments. The single-line production capacity of Targeted Therapy Drugs for Cancer varies significantly depending on the drug molecule type, process complexity, equipment scale, and production mode. Industry gross margins typically range from 60% to 80%. United States market for Targeted Therapy Drugs for Cancer is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032. China market for Targeted Therapy Drugs for Cancer is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032. Europe market for Targeted Therapy Drugs for Cancer is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032. Global key Targeted Therapy Drugs for Cancer players cover Roche, Novartis, Merck, Pfizer, AstraZeneca, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025. Infinity Market Research newest research report, the ?Targeted Therapy Drugs for Cancer Industry Forecast? looks at past sales and reviews total world Targeted Therapy Drugs for Cancer sales in 2025, providing a comprehensive analysis by region and market sector of projected Targeted Therapy Drugs for Cancer sales for 2026 through 2032. With Targeted Therapy Drugs for Cancer sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Targeted Therapy Drugs for Cancer industry. This Insight Report provides a comprehensive analysis of the global Targeted Therapy Drugs for Cancer landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Targeted Therapy Drugs for Cancer portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Targeted Therapy Drugs for Cancer market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Targeted Therapy Drugs for Cancer and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Targeted Therapy Drugs for Cancer. This report presents a comprehensive overview, market shares, and growth opportunities of Targeted Therapy Drugs for Cancer market by product type, application, key manufacturers and key regions and countries. Segmentation by Type: &nbsp;&nbsp;&nbsp; Kinase Inhibitors &nbsp;&nbsp;&nbsp; ADCs &nbsp;&nbsp;&nbsp; Others &nbsp;&nbsp;&nbsp; Segmentation by Administration Route: &nbsp;&nbsp;&nbsp; Oral Drugs &nbsp;&nbsp;&nbsp; Injectable Drugs &nbsp;&nbsp;&nbsp; Others &nbsp;&nbsp;&nbsp; Segmentation by Molecular Properties: &nbsp;&nbsp;&nbsp; Small Molecule Drugs &nbsp;&nbsp;&nbsp; Antibody Drugs &nbsp;&nbsp;&nbsp; Others Segmentation by Application: &nbsp;&nbsp;&nbsp; Lung Cancer &nbsp;&nbsp;&nbsp; Breast Cancer &nbsp;&nbsp;&nbsp; Colorectal Cancer &nbsp;&nbsp;&nbsp; Stomach Cancer &nbsp;&nbsp;&nbsp; Liver Cancer &nbsp;&nbsp;&nbsp; Others This report also splits the market by region: &nbsp;&nbsp;&nbsp; Americas &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; United States &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Canada &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mexico &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Brazil &nbsp;&nbsp;&nbsp; APAC &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; China &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Japan &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Korea &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Southeast Asia &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; India &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Australia &nbsp;&nbsp;&nbsp; Europe &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Germany &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; France &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UK &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Italy &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Russia &nbsp;&nbsp;&nbsp; Middle East & Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Egypt &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; South Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Israel &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turkey &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the companys coverage, product portfolio, its market penetration. &nbsp;&nbsp;&nbsp; Roche &nbsp;&nbsp;&nbsp; Novartis &nbsp;&nbsp;&nbsp; Merck &nbsp;&nbsp;&nbsp; Pfizer &nbsp;&nbsp;&nbsp; AstraZeneca &nbsp;&nbsp;&nbsp; Johnson & Johnson &nbsp;&nbsp;&nbsp; Bristol Myers Squibb &nbsp;&nbsp;&nbsp; Bayer &nbsp;&nbsp;&nbsp; GSK &nbsp;&nbsp;&nbsp; Daiichi Sankyo &nbsp;&nbsp;&nbsp; Amgen &nbsp;&nbsp;&nbsp; Eli Lilly and Company &nbsp;&nbsp;&nbsp; AbbVie &nbsp;&nbsp;&nbsp; Sanofi &nbsp;&nbsp;&nbsp; Takeda &nbsp;&nbsp;&nbsp; Boehringer Ingelheim &nbsp;&nbsp;&nbsp; Beigene, Ltd. &nbsp;&nbsp;&nbsp; Jiangsu Hengrui Medicine &nbsp;&nbsp;&nbsp; INNOVENT BIOLOGICS(SUZHOU) &nbsp;&nbsp;&nbsp; Betta Pharmaceuticals &nbsp;&nbsp;&nbsp; Remegen Co.,Ltd. &nbsp;&nbsp;&nbsp; Shanghai Allist Pharmaceuticals &nbsp;&nbsp;&nbsp; Innocare &nbsp;&nbsp;&nbsp; Huiyu Pharmaceuticals Key Questions Addressed in this Report What is the 10-year outlook for the global Targeted Therapy Drugs for Cancer market? What factors are driving Targeted Therapy Drugs for Cancer market growth, globally and by region? Which technologies are poised for the fastest growth by market and region? How do Targeted Therapy Drugs for Cancer market opportunities vary by end market size? How does Targeted Therapy Drugs for Cancer break out by Type, by Application?

Report	Global Targeted Therapy Drugs for Cancer Market Size, Share and Analysis Report 2026-2032
Selected License	Multi ID: ILR5115

Buyer Information

Order Summary